Factors Likely to Have Influenced Earnings Results Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Earnings results for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. is estimated to report earnings on 02/22/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.97.

Analyst Opinion on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

7 Wall Street analysts have issued ratings and price targets for Zentalis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.14, predicting that the stock has a possible upside of 43.30%. The high price target for ZNTL is $75.00 and the low price target for ZNTL is $41.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Zentalis Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $51.14, Zentalis Pharmaceuticals has a forecasted upside of 43.3% from its current price of $35.69. Zentalis Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals does not currently pay a dividend. Zentalis Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL)

In the past three months, Zentalis Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,659,887.00 in company stock. 67.13% of the stock of Zentalis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Zentalis Pharmaceuticals (NASDAQ:ZNTL

Earnings for Zentalis Pharmaceuticals are expected to grow in the coming year, from ($4.69) to ($2.90) per share.

More latest stories: here